In October, we added 115 citations in DIDB, including 55 in vitro (with 23 articles published in October 2024) and 60 in vivo articles (with 35 articles published in October 2024).
3 NDA/BLAs approved in 2024, including lebrikizumab (EBGLYSS), levacetylleucine (AQNEURSA), and flurpiridaz F18 (FLYRCADO) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.